Dekavil at the EULAR 2013

I’ve seen a poster on dekavil at the EULAR 2013 meeting. Let’s return to the ACR 2012 meeting for a moment. I’d written:
“Maybe we have to wait for a couple of years to evaluate dekavil. If the results are as good as shown in the abstract, then it could develop into a block buster. Philogen S.p.A. hasn’t rushed yet to large scale international multicenter studies and I interpret this as a hint, that the potential of this drug isn’t as high as the study of M. Galeazzi wants us to believe.”

M. Galeazzi and colleagues presented [SAT0108]: Dekavil (F8-IL10): a novel anti-inflammatory immunocytokine for the treatment of rheumathoid arthritis”. Conclusions: “The promising safety data regarding the clinical use of F8-IL10, together with preliminary positive signs of activity, suggest that the targeted delivery of IL10 to the site of inflammation may be beneficial to patients with RA. These results also warrant future developments of the product in randomized clinical trials. An update of clinical data will be presented.”

That’s not so different from the text presented at the ACR 2012: “The promising safety data regarding the clinical use of F8-IL10, together with preliminary positive signs of activity may be favored by the targeted delivery of IL10 to the site of inflammation. These results also warrant future developments of the product in randomized clinical trials, which are currently in planning. An update of clinical data will be presented at the ACR meeting.”
Please promise to publish more than promising data at the ACR 2013 at the next ACR meeting.

Links:

http://rheumatologe.blogspot.de/2012/12/dekavil-at-acr-2012-in-washington.html
http://rheumatologe.blogspot.de/2012/07/dekavil-at-eular-2012.html